You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Anti-PD-1 monoclonal antibody (mAb)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced NSCLC Trial in Nanjing (AK104, Docetaxel)

Recruiting
  • Advanced Non-small Cell Lung Cancer
  • Nanjing, Jiangsu, China
    Jiangsu Cancer Hospital
Mar 24, 2022

Advanced Solid Tumor, Metastatic Cancer, Refractory Cancer Trial in Huntersville, Houston, Webster (PT199, Anti-PD-1 mAb)

Recruiting
  • Advanced Solid Tumor
  • +18 more
  • PT199
  • Anti-PD-1 monoclonal antibody
  • Huntersville, North Carolina
  • +2 more
Aug 10, 2022

NSCLC Trial in Shanghai (Capsulized Fecal Microbiota Transplant, Anti-programmed cell death protein 1/programmed death-ligand 1

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • Capsulized Fecal Microbiota Transplant
  • +2 more
  • Shanghai, Shanghai, China
    Zhongshan Hospital, Fudan University
Aug 12, 2021

Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Unresectable Malignant Solid Tumor Trial in Houston

Active, not recruiting
  • Advanced Malignant Solid Neoplasm
  • +2 more
  • Anti-TGF-beta Monoclonal Antibody SAR-439459
  • Cemiplimab
  • Houston, Texas
    M D Anderson Cancer Center
Feb 9, 2022

NSCLC Stage IV Trial (HLX26, Serplulimab, Pemetrexed)

Not yet recruiting
  • NSCLC Stage IV
  • (no location specified)
Mar 15, 2023

Pancreatic Ductal Adenocarcinoma, Refractory NSCLC Trial in Washington (Daratumumab, KRAS vaccine, Nivolumab)

Not yet recruiting
  • Pancreatic Ductal Adenocarcinoma
  • Refractory Non-Small Cell Lung Cancer
  • Washington, District of Columbia
    Georgetown Lombardi Comprehensive Cancer Center
Sep 1, 2023

Solid Tumors Trial (GS-9911, Zimberelimab)

Not yet recruiting
  • Solid Tumors
  • (no location specified)
Oct 9, 2023

Solid Tumor, Adult Trial in Australia (IOS-1002, IOS-1002 + PD-1 mAb)

Recruiting
  • Solid Tumor, Adult
  • Clayton, Australia
  • +4 more
Mar 15, 2023

Colorectal Cancer Trial in Hangzhou (Ametumumab, Anti-PD-1 mAb, Cetuximab)

Not yet recruiting
  • Colorectal Cancer
  • Hangzhou, Zhejiang, China
    Sir Run Run Shaw Hospital, Zhejiang University School of Medicin
Jan 30, 2023

Nasopharyngeal Carcinoma Trial in Shanghai (Anti-EGFR and PD-1 inhibitor arm)

Recruiting
  • Nasopharyngeal Carcinoma
  • Anti-EGFR and PD-1 inhibitor arm
  • Shanghai, Shanghai, China
    Eye & ENT Hospital of Fudan University
Nov 26, 2023

Adenocarcinoma, Stomach Tumor, Gastroesophageal-junction Cancer Trial in Shanghai (radiation, biological, drug, procedure)

Recruiting
  • Adenocarcinoma
  • +8 more
  • Radiotherapy targeted to the primary lesion
  • +7 more
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Nov 7, 2023

Solid Tumor Trial (GS-4528, Zimberelimab)

Not yet recruiting
  • Solid Tumor
  • (no location specified)
Apr 21, 2023

Rectal Cancer Trial (Short-course radiotherapy combined with furoquintinib and PD-1 mAb)

Not yet recruiting
  • Rectal Cancer
  • Short-course radiotherapy combined with furoquintinib and PD-1 monoclonal antibody
  • (no location specified)
Aug 29, 2023

Pyoderma, Pyoderma Gangrenosum, Pyoderma Vegetans Trial in Minsk, Riga (Monoclonal antibody (Mab) sB24M)

Active, not recruiting
  • Pyoderma
  • +3 more
  • Monoclonal antibody (Mab) sB24M
  • Minsk, Belarus
  • +1 more
Jul 8, 2022

Colorectal Cancer Trial (Serplulimab + FOLFOXIRI, Radiation therapy)

Not yet recruiting
  • Colorectal Cancer
  • Serplulimab + FOLFOXIRI
  • Radiation therapy
  • (no location specified)
Oct 24, 2023

Bevacizumab Combined With PD-1 Monoclonal Antibody in

Not yet recruiting
  • Colorectal Cancer
  • Bevacizumab Combined With PD-1 Monoclonal Antibody
  • (no location specified)
Nov 8, 2023

Anti-PD-1 Antibody Combined With Chemotherapy for Neoadjuvant

Active, not recruiting
  • Locally Advanced Gastric Adenocarcinoma
  • PD-1
  • DNA panel and RNA Sequencing
  • Xi'an, Shaanxi, China
    Xijing Hospital of Digestive Diseases
Aug 17, 2022

Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Merkel Cell

Not yet recruiting
  • Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8
  • +2 more
  • Biopsy
  • +6 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Sep 28, 2023

Multiple Cancer, Colorectal Cancer Trial (MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 mAb neoadjuvant

Not yet recruiting
  • Multiple Cancer
  • Colorectal Cancer
  • MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 monoclonal antibody neoadjuvant therapy
  • All-MSI-H (dMMR) sMPCC: single-drug PD-1 monoclonal antibody neoadjuvant therapy
  • (no location specified)
Aug 20, 2023

Idiopathic Multicentric Castleman's Disease Trial in Beijing, Chengdu (Recombinant Humanized Anti-interleukin-6 Receptor

Recruiting
  • Idiopathic Multicentric Castleman's Disease
  • Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection 4mg/kg
  • +2 more
  • Beijing, China
  • +2 more
Apr 26, 2022

Rheumatoid Arthritis Trial in China (IL-6R Monoclonal Antibody Injection 4mg/kg, IL-6R Monoclonal Antibody Injection 6mg/kg,

Completed
  • Rheumatoid Arthritis
  • IL-6R Monoclonal Antibody Injection 4mg/kg
  • +3 more
  • Baoding, China
  • +4 more
Feb 24, 2022

Advanced Lung Carcinoma Trial in Beijing (LK101 injection (personlized neoantigen pulsed DC vaccine ), Pembrolizumab,

Recruiting
  • Advanced Lung Carcinoma
  • LK101 injection (personlized neoantigen pulsed DC vaccine )
  • +2 more
  • Beijing, Beijing, China
    Cancer hospital Chinese Academy of Medical Sciences
May 23, 2023

Melanoma, NSCLC, Hepatocellular Carcinoma Trial in Pittsburgh (Nivolumab or Pembrolizumab (dependent upon approved indication),

Recruiting
  • Melanoma
  • +7 more
  • Nivolumab or Pembrolizumab (dependent upon approved indication)
  • +2 more
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Feb 10, 2022

Hepatitis b Virus Trial in New York (HepB mAb19, Sterile Saline)

Not yet recruiting
  • Hepatitis b Virus
  • HepB mAb19
  • Sterile Saline
  • New York, New York
  • +1 more
May 12, 2023

MSS, Rectal Cancer Trial (Sintilimab with Interleukin-2)

Not yet recruiting
  • MSS
  • Rectal Cancer
  • Sintilimab with Interleukin-2
  • (no location specified)
Nov 1, 2023